139 related articles for article (PubMed ID: 7357075)
1. Pretreatment tumor mass, cell kinetics, and prognosis in multiple myeloma.
Durie BG; Salmon SE; Moon TE
Blood; 1980 Mar; 55(3):364-72. PubMed ID: 7357075
[TBL] [Abstract][Full Text] [Related]
2. A new improved clinical staging system for multiple myeloma based on analysis of 123 treated patients.
Merlini G; Waldenström JG; Jayakar SD
Blood; 1980 Jun; 55(6):1011-9. PubMed ID: 7378577
[TBL] [Abstract][Full Text] [Related]
3. [Prognostic factors in IgG and micromolecular multiple myeloma. Retrospective analysis of 50 consecutive cases].
Pasqualetti P; Casale R; Colantonio D; Festuccia V; Di Lauro G; Natali G
Minerva Med; 1987 May; 78(9):603-8. PubMed ID: 3587727
[TBL] [Abstract][Full Text] [Related]
4. A new staging system for multiple myeloma based on the number of S-phase plasma cells.
San Miguel JF; García-Sanz R; González M; Moro MJ; Hernández JM; Ortega F; Borrego D; Carnero M; Casanova F; Jiménez R
Blood; 1995 Jan; 85(2):448-55. PubMed ID: 7811998
[TBL] [Abstract][Full Text] [Related]
5. Classification and prognostic evaluation in multiple myeloma. A retrospective study of relationship of survivals and responses to chemotherapy to immunological types, 20 single prognostic factors, 15 clinical staging systems, and 6 morphological classifications.
Pasqualetti P; Colantonio D; Collacciani A; Casale R; Natali G
Panminerva Med; 1991; 33(2):93-110. PubMed ID: 1923560
[TBL] [Abstract][Full Text] [Related]
6. [The wide variations of the clinical behavior and prognosis in multiple myeloma].
Kanoh T; Hirashimizu K
Rinsho Ketsueki; 1993 Apr; 34(4):439-43. PubMed ID: 8510330
[TBL] [Abstract][Full Text] [Related]
7. Determination of plasma cell secreting potential as an index of maturity of myelomatous cells and a strong prognostic factor.
Symeonidis A; Kouraklis-Symeonidis A; Grouzi E; Zolota V; Melachrinou M; Kourea K; Fragopanagou E; Giannakoulas N; Seimeni U; Tiniakou M; Matsouka P; Zoumbos N
Leuk Lymphoma; 2002 Aug; 43(8):1605-12. PubMed ID: 12400603
[TBL] [Abstract][Full Text] [Related]
8. Prognostic factors in IgD myeloma: a study of 21 cases.
Fibbe WE; Jansen J
Scand J Haematol; 1984 Nov; 33(5):471-5. PubMed ID: 6515330
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and metabolism of Bence Jones protein and calculation of tumour burden in patients with Bence Jones myeloma.
Durie BG; Cole PW; Chen HS; Himmelstein KJ; Salmon SE
Br J Haematol; 1981 Jan; 47(1):7-19. PubMed ID: 7437347
[TBL] [Abstract][Full Text] [Related]
10. [Prognostic factors in multiple myeloma. Selection using multivariate analysis].
Pasqualetti P; Colantonio D; Casale R; Lorenzetti G; Natali G
Recenti Prog Med; 1989 Oct; 80(10):543-6. PubMed ID: 2602637
[TBL] [Abstract][Full Text] [Related]
11. [Relation between certain parameters of renal function and prognosis in multiple myeloma].
Cengic M; Robovic Z; Rasic S; Golemac S
Med Arh; 2001; 55(4):193-5. PubMed ID: 11769440
[TBL] [Abstract][Full Text] [Related]
12. Prognostic value of the staging system proposed by Merlini, Waldenström and Jayakar for multiple myeloma.
Bettini R; Steidl L; Rapazzini P; Giardina G
Acta Haematol; 1983; 70(6):379-85. PubMed ID: 6417962
[TBL] [Abstract][Full Text] [Related]
13. Serum beta2 microglobulin and survival duration in multiple myeloma: a simple reliable marker for staging.
Bataille R; Durie BG; Grenier J
Br J Haematol; 1983 Nov; 55(3):439-47. PubMed ID: 6357266
[TBL] [Abstract][Full Text] [Related]
14. Prognostic factors affecting the survival of patients with multiple myeloma. A retrospective analysis of 86 patients.
Rapoport BL; Falkson HC; Falkson G
S Afr Med J; 1991 Jan; 79(2):65-7. PubMed ID: 1989088
[TBL] [Abstract][Full Text] [Related]
15. Prognostic factors in multiple myeloma: a new staging system based on clinical and morphological features.
Pasqualetti P; Casale R; Collacciani A; Colantonio D
Eur J Cancer; 1991; 27(9):1123-6. PubMed ID: 1835621
[TBL] [Abstract][Full Text] [Related]
16. Value of beta 2-microglobulin level and plasma cell labeling indices as prognostic factors in patients with newly diagnosed myeloma.
Greipp PR; Katzmann JA; O'Fallon WM; Kyle RA
Blood; 1988 Jul; 72(1):219-23. PubMed ID: 3291982
[TBL] [Abstract][Full Text] [Related]
17. Prognostic factors and classification in multiple myeloma.
San Miguel JF; Sànchez J; Gonzalez M
Br J Cancer; 1989 Jan; 59(1):113-8. PubMed ID: 2757917
[TBL] [Abstract][Full Text] [Related]
18. Multiple myeloma with massive Bence Jones proteinuria and preservation of renal function.
Woodruff R; Sweet B
Aust N Z J Med; 1977 Feb; 7(1):60-2. PubMed ID: 266896
[TBL] [Abstract][Full Text] [Related]
19. Peripheral blood monoclonal plasma cells as a predictor of survival in patients with multiple myeloma.
Witzig TE; Gertz MA; Lust JA; Kyle RA; O'Fallon WM; Greipp PR
Blood; 1996 Sep; 88(5):1780-7. PubMed ID: 8781435
[TBL] [Abstract][Full Text] [Related]
20. "Idiopathic" Bence Jones proteinuria: long-term follow-up in seven patients.
Kyle RA; Greipp PR
N Engl J Med; 1982 Mar; 306(10):564-7. PubMed ID: 7057813
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
